Avacta Selects Zeus as Joint Broker for Strategic Growth
Deal News | Jul 01, 2025 | Zeus Capital
Zeus Capital has been appointed as the Joint Broker for Avacta Group plc, a clinical-stage biotechnology firm listed on AIM with the ticker AVCT. Avacta focuses on enhancing cancer therapies through its pre|CISION platform and boasts cutting-edge research facilities and a highly skilled team. The company operates from its headquarters in London and also has a presence in the United States. This partnership aims to leverage Zeus Capital’s financial acumen to support Avacta’s strategic objectives and strengthen its position in the biotechnology sector.
Sectors
- Biotechnology
- Financial Services
Geography
- United Kingdom – Avacta Group plc is headquartered in London and is listed on the AIM market, highlighting its British roots and operations.
- United States – Avacta also has a presence in the US, indicating its international operational reach.
Industry
- Biotechnology – Avacta Group plc operates in the biotechnology sector, focusing on cancer therapies and leveraging the pre|CISION platform.
- Financial Services – Zeus Capital provides investment banking services, including brokerage activities, making it an integral player in financial transactions in the biotech sector.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Avacta Group plc | Target Company | Company | A clinical-stage biotechnology company working on cancer therapies and listed on AIM. |
| Zeus Capital | Joint Broker | Company | An investment bank providing brokerage services to support Avacta’s strategic and financial goals. |